Skip to main content
Premium Trial:

Request an Annual Quote

Veracyte Inks Research Collaboration with GE

NEW YORK (GenomeWeb) – Veracyte today announced that it has signed a research collaboration agreement with GE to develop new diagnostic approaches based on GE Healthcare's digital imaging technology.

The partners will "explore the concept of deriving innovative diagnostic approaches from a combination of digital imaging and genomic technologies," Veracyte CEO Bonnie Anderson said in a statement.

The firms will look to identify features from raw imaging data that, when combined with genomic information, have the potential to inform disease diagnosis.

Veracyte has amassed a large database of clinical, imaging, and genomic information from clinical trials to validate its Afirma gene expression classifier (GEC) tests, the firm said in a statement.

Under the terms of the agreement, Veracyte will collaborate with GE Ventures, GE Healthcare, and the GE Global Research Center to assess the feasibility of combining the two firms' technologies.

Financial and other terms of the agreement were not disclosed.

Last month, Veracyte expanded a co-promotion deal for the Afirma GEC test in Brazil and Singapore with Genzyme.